Goldman Sachs Initiates Coverage On Mineralys Therapeutics with Buy Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Richard Law initiates coverage on Mineralys Therapeutics (MLYS) with a Buy rating and a price target of $30.

April 02, 2024 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs initiated coverage on Mineralys Therapeutics with a Buy rating and a price target of $30.
The initiation of coverage by a major financial institution like Goldman Sachs, especially with a Buy rating and a significant price target, is likely to generate positive investor sentiment towards MLYS in the short term. This could lead to an increase in stock price as investors react to the new coverage and price target.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100